ArticleJournal of cardiothoracic surgery2026
Impact of cardiohepatic syndrome on postoperative mortality in heart failure patients with reduced ejection fraction undergoing coronary artery bypass grafting.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimCardiohepatic syndrome (CHS) is a parameter used to define liver dysfunction in heart failure patients and has been shown to be associated with poor prognosis. In this study, we investigated the relationship between the presence of preoperative CHS and postoperative mortality in heart failure patients with reduced ejection fraction (HFrEF) undergoing coronary artery bypass grafting (CABG). MATERIALS AND
methodsWe retrospectively included patients who were evaluated in anesthesia outpatient clinic of our hospital before first-time elective isolated CABG and had HFrEF (left ventricular ejection fraction [LVEF] ≤ 40%) between 2019 and 2023 years. Patients’ demographic, clinical and laboratory parameters were recorded and patients were divided into two according to the presence of CHS. Primary outcome of the study was long-term all-cause mortality. The median follow-up duration was 607 days (interquartile range [IQR]: 484–773 days).
resultsA total of 299 patients with a median age 62 years (IQR: 56–69 years) were enrolled. 80% (n = 240) of the study group were men and CHS was observed in 8% (n = 24) of the patients. All-cause mortality occurred in 50 patients (16.7%) during the follow-up. CHS was more common in mortality (+) group (14% vs. 6.8%, p = 0.049). Presence of CHS was associated with a significant increase in all-cause mortality (adjusted hazard ratio: 2.93; 95% confidence interval: 1.18–7.24; p = 0.02) along with advanced age, high creatinine, low albumin and LVEF values.
conclusionPresence of preoperative CHS was independently associated with long term all-cause mortality in HFrEF patients undergoing CABG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.